Prognostic and immunotherapeutic implications of bilirubin metabolism-associated genes in lung adenocarcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a prognostic signature using bilirubin metabolism-associated genes (BMAGs) to predict outcomes in lung adenocarcinoma (LUAD). The signature effectively identified patient risk and predicted immunotherapy response, offering new strategies for LUAD treatment.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Genomics
Background
- Lung adenocarcinoma (LUAD) is a significant cause of cancer mortality.
- The role of bilirubin metabolism in cancer, particularly LUAD and immunotherapy response, requires further investigation.
Purpose Of The Study
- To develop a prognostic signature based on bilirubin metabolism-associated genes (BMAGs) for LUAD.
- To predict patient outcomes and immunotherapy efficacy in LUAD using the BMAG signature.
- To identify potential therapeutic targets within the identified BMAGs.
Main Methods
- Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets for gene expression.
- Construction and validation of a prognostic model using survival-related BMAGs.
- Somatic mutation profiling and assessment of immune cell infiltration and checkpoint expression.
Main Results
- A novel BMAG-based prognostic signature was developed and validated, effectively stratifying LUAD patients into distinct risk groups with differential survival.
- The BMAG signature served as an independent prognostic factor, outperforming traditional clinical parameters.
- The low-risk group demonstrated a better response to immunotherapy, characterized by higher immune checkpoint expression and immune cell infiltration.
- Fructose-1,6-bisphosphatase 1 (FBP1) was identified as a tumor-suppressive gene in LUAD, inhibiting proliferation, migration, and invasion.
Conclusions
- The developed BMAG signature is a potent prognostic indicator for LUAD, offering valuable insights for patient prognostication.
- This signature can aid in tailoring immunotherapy strategies for LUAD patients.
- Targeting specific BMAGs, such as the tumor-suppressive FBP1, presents potential therapeutic avenues for LUAD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
